Showing results (71-80 of 102) with videos related to
Sort By:
Pageof 11
International Journal of Pediatric Otorhinolaryngology|August 31, 2006
The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunctionCharles S Ebert, Austin S Rose, Mihir R Patel, et al.Vaccine|March 25, 2010
A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccineAntonella Conforti, Barbara Cipriani, Daniela Peruzzi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancerRoberto Bianco, Roberta Caputo, Rosa Caputo, et al.Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|August 2, 2007
Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in ratsCharles S Ebert, Austin S Rose, Deidra A Blanks, et al.International Journal of Oncology|June 14, 2002
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenograftsSudhir Agrawal, Ekambar R Kandimalla, Dong Yu, et al.Nucleic Acids Research|April 25, 2003
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profilesEkambar R Kandimalla, Lakshmi Bhagat, Daqing Wang, et al.Autoimmunity|October 3, 2013
A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 miceFu-Gang Zhu, Weiwen Jiang, Lakshmi Bhagat, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2016
RAGE Enhances TLR Responses through Binding and Internalization of RNADamien Bertheloot, Allison L Naumovski, Pia Langhoff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancersRoberta Rosa, Davide Melisi, Vincenzo Damiano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitorsVincenzo Damiano, Rosa Caputo, Roberto Bianco, et al.Pageof 11